Keeping Cancer In The Crosshairs

Keeping Cancer In The Crosshairs

Keeping Cancer In The Crosshairs With Targeted Therapies One of the biggest stories in last week’s biotech news headlines was Pfizer’s (New York, NY) acquisition of Array Biopharma (Boulder, CO) for the tidy sum of $11 billion. Array specializes in targeted cancer...
Post-translational Modifications In Biotech

Post-translational Modifications In Biotech

Basic Science Meets Application “Post-translational modification” may not be a term you hear every day, but it is critically important to the biotech industry—from understanding how cancer develops to producing biologics. Breaking the term down, we know that: “post”...